版本:
中国

BRIEF-Glycomimetics reports qtrly net loss per share of $0.34

May 8 Glycomimetics Inc

* Glycomimetics reports program updates and first quarter 2017 results

* Qtrly net loss per share $0.34

* Qtrly loss per share $0.34

* Phase 3 program to evaluate Rivipansel for vaso-occlusive sickle cell crisis, according to Pfizer, remains on track for completion in H2 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐